Blog
When biotechs get breakthrough therapy status, Mr. Market yawns
As Jay-Z might say, breakthrough status may provide 99 benefits, but excess stock returns ain’t one.
How to prevent drug price shenanigans
Drug price scandals aren’t all the same - but here’s one that may be preventable.
Is FDA's annual new drug count a nothingburger?
FDA approved 46 new drugs so far in 2017. But are they the drugs we need?
Did “Medicus economicus” kill Medicare Part B reform?
It's surprisingly hard to figure out how much oncologists make from office-infused drugs, but we gave it our best shot.
New data in the FDA deregulation debate
Should FDA automatically approve drugs available in other countries? The potential clinical benefits may be overstated.